Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
about
Optimal management of idiopathic macular holesOcriplasmin for Treatment of Vitreomacular Traction: An UpdateRedesigning services for the management of vitreomacular traction and macular hole.Transient visual loss and delayed resolution of vitreomacular traction after intravitreal ocriplasmin.Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomographyOcriplasmin for treatment of stage 2 macular holes: early clinical results.A review of current management of vitreomacular traction and macular hole.Acute ocriplasmin retinopathyThe Ultrastructural Localization of Type II, IV, and VI Collagens at the Vitreoretinal Interface.Comparison of Guided and Unguided Ocriplasmin Injection for the Treatment of Vitreomacular Traction: A Preliminary Study.Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study.Clinical characteristics and selection of treatment modality for patients with vitreomacular traction: real-world implementation of NICE guidance (TA297).Macular hole formation and spontaneous closure after vitrectomy for rhegmatogenous retinal detachment documented by spectral-domain optical coherence tomography: Case report and literature review.The design and validation of an optical coherence tomography-based classification system for focal vitreomacular tractionPredicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomographyRhegmatogenous retinal detachment following intravitreal ocriplasmin.Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders.Volumetric ellipsoid zone mapping for enhanced visualisation of outer retinal integrity with optical coherence tomography.Incomplete vitreomacular traction release using intravitreal ocriplasmin.Macular Hole Progression following Ocriplasmin Intravitreal Injection.Assessment of Ocriplasmin Effects on the Vitreoretinal Compartment in Porcine and Human Model Systems.ELLIPSOID ZONE MAPPING AND OUTER RETINAL CHARACTERIZATION AFTER INTRAVITREAL OCRIPLASMIN.Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
P2860
Q26772860-E44E279F-9D2E-45A1-B3D8-F56A86CF51BAQ28077014-72099BEE-AA38-4C6D-B1DE-C0FE12016C69Q33898373-F4ED03F0-8FA0-4B23-80B8-802905889766Q34610521-5705672D-8895-42F9-B5ED-6AEDFDCBB136Q34617273-2943F987-FDD0-4ABC-8346-399A134775ACQ35127563-47420E22-338A-4C09-90FD-223FE3EF6422Q35188796-F038EDAC-119D-474D-8B19-C134222AE349Q35688041-7A9F8DBC-BE20-4F1A-B44F-00F72303EEA0Q35730271-5156BA35-0231-4B1F-AF33-04F8006951E5Q35986142-134EA886-A6F8-46CA-A374-DABF9F5C5235Q36080714-BA56CF05-9BDF-4994-9861-39A0388A4FD5Q36340600-70D65B15-D9E6-49CD-BDC9-254FC6491857Q36473593-44DB8672-B0C1-4D91-A1E4-9411A356DC2CQ36508383-C4F9591D-9F31-4B5E-A54E-2F17642EC1EAQ36605694-A2F43491-951D-4F5F-A4FB-1D864D9CE176Q36906903-546C6D75-0C87-4FB9-B517-D217BF694015Q37424148-A3C7A6FE-052B-42CF-84FA-C9FCD800E78EQ38262441-0FEA375B-5689-4180-AF6E-9A4A04E444F3Q38823462-C663A886-4F56-4F43-860D-3F462501D6D9Q38889157-CF062231-0314-4DCD-AB53-8DFCB542E7BDQ38992388-DA650096-E18D-4D03-8C10-39EAA5268773Q39024789-995EBF53-8354-4DDE-974C-47128B808749Q40708022-49360C90-EB31-4221-A23B-82E0DAD6DBCAQ42007511-777267A4-185B-4302-A0BE-817887CC6A1EQ43085341-56EF84C3-A368-40DB-8681-108A384C6607Q45331770-C09F5331-3B2E-415D-81DA-102B59532EBDQ46831213-C0426C23-30B0-4502-BBD1-594F5AD96D2FQ48296372-969C51BC-766E-44FF-9134-E1010F4AFA34Q48326718-91821074-CE94-4F1E-9C9C-20515B0B4340Q51027710-34709F63-7519-4F65-BA86-82269D89A6F2Q52665330-976F1EF1-D9E2-40E0-9561-1C5593C441EEQ52872225-A9276254-46B1-4D0E-96B8-DC90BAF95BE7
P2860
Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Anatomical and visual outcomes ...... treomacular traction syndrome.
@en
Anatomical and visual outcomes ...... treomacular traction syndrome.
@nl
type
label
Anatomical and visual outcomes ...... treomacular traction syndrome.
@en
Anatomical and visual outcomes ...... treomacular traction syndrome.
@nl
prefLabel
Anatomical and visual outcomes ...... treomacular traction syndrome.
@en
Anatomical and visual outcomes ...... treomacular traction syndrome.
@nl
P2093
P2860
P1476
Anatomical and visual outcomes ...... itreomacular traction syndrome
@en
P2093
Andrew P Schachat
Jonathan E Sears
Justis P Ehlers
Rishi P Singh
Rumneek Bedi
Sunil Srivastava
P2860
P304
P356
10.1136/BJOPHTHALMOL-2013-304219
P407
P577
2013-12-19T00:00:00Z